CA2427618A1 - Composition contenant des statines et du calcium destinee a ameliorer la sante cardiovasculaire - Google Patents

Composition contenant des statines et du calcium destinee a ameliorer la sante cardiovasculaire Download PDF

Info

Publication number
CA2427618A1
CA2427618A1 CA002427618A CA2427618A CA2427618A1 CA 2427618 A1 CA2427618 A1 CA 2427618A1 CA 002427618 A CA002427618 A CA 002427618A CA 2427618 A CA2427618 A CA 2427618A CA 2427618 A1 CA2427618 A1 CA 2427618A1
Authority
CA
Canada
Prior art keywords
vitamin
composition
composition according
mixture contains
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002427618A
Other languages
English (en)
Inventor
Adrianne Bendich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2427618A1 publication Critical patent/CA2427618A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition destinée à être administrée par voie orale, contenant un mélange d'une statine, d'acide docosahexaenoïque (DHA), de vitamine E, de vitamine C, de vitamine B6, de vitamine B12, d'acide folique, et de calcium avec un porteur adapté. Ces compositions sont particulièrement adaptées en tant qu'additifs alimentaires administrés pour réduire les facteurs de risque de maladies cardiovasculaires, tels que des taux de cholestérol sérique et une pression artérielle élevés.
CA002427618A 2000-11-29 2001-11-29 Composition contenant des statines et du calcium destinee a ameliorer la sante cardiovasculaire Abandoned CA2427618A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25389900P 2000-11-29 2000-11-29
US60/253,899 2000-11-29
PCT/US2001/044734 WO2002043659A2 (fr) 2000-11-29 2001-11-29 Composition contenant des statines et du calcium destinee a ameliorer la sante cardiovasculaire

Publications (1)

Publication Number Publication Date
CA2427618A1 true CA2427618A1 (fr) 2002-06-06

Family

ID=22962156

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002427618A Abandoned CA2427618A1 (fr) 2000-11-29 2001-11-29 Composition contenant des statines et du calcium destinee a ameliorer la sante cardiovasculaire

Country Status (6)

Country Link
EP (1) EP1339429A4 (fr)
JP (1) JP2004514684A (fr)
AU (1) AU3651102A (fr)
CA (1) CA2427618A1 (fr)
MX (1) MXPA03004818A (fr)
WO (1) WO2002043659A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4611622B2 (ja) * 2002-07-11 2011-01-12 第一三共株式会社 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
CA2492781A1 (fr) * 2002-07-11 2004-01-22 Sankyo Company Limited Composition medicale pour reduire le taux de lipides sanguins ou le taux d'homocysteine sanguine
US20040092590A1 (en) * 2002-09-27 2004-05-13 Linda Arterburn Glycemic control for prediabetes and/or diabetes Type II using docosahexaenoic acid
EP1551382A4 (fr) * 2002-09-27 2007-01-24 Martek Biosciences Corp Therapie prophylactique a l'acide docosahexaenoique pour patients atteints d'inflammation subclinique
FR2847472B1 (fr) * 2002-11-22 2006-08-11 Synergia Nouvelles compositions pharmaceutiques notamment pour la prevention des pathologies cardio-vasculaires
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
AU2004305154A1 (en) * 2003-12-23 2005-07-07 Medicure International Inc. Combination therapies employing a composition comprising a HMG CoA reductase inhibitor and a vitamin B6 related compound
ITRM20040395A1 (it) * 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
EP1786414A4 (fr) * 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc Nouvelles compositions pharmaceutiques a base de statines et methodes de traitement associees
US20070259022A1 (en) * 2004-08-23 2007-11-08 Molhuizen Henricus O F Composition Comprising Statin
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EA014420B1 (ru) * 2004-12-06 2010-12-30 Релайэнт Фармасьютикалз, Инк. Омега-3 жирные кислоты и дислипидемический агент для липидной терапии
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
MX2008001597A (es) * 2005-08-04 2008-04-04 Transform Pharmaceuticals Inc Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
CN101309679B (zh) * 2005-11-11 2013-07-24 持田制药株式会社 胶冻组合物
EP2081550B2 (fr) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Revêtement de capsules avec des ingrédients pharmaceutiques actifs
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
ITMI20072142A1 (it) * 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3
KR20110039249A (ko) * 2008-07-07 2011-04-15 모치다 세이야쿠 가부시키가이샤 지질 이상증의 개선 또는 치료약
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
WO2011047259A1 (fr) * 2009-10-16 2011-04-21 Glaxosmithkline Llc Compositions
WO2011078712A1 (fr) 2009-12-23 2011-06-30 Dafiante Farmacêutica S.A. Composition de combinaison utile pour le traitement de maladies cardiovasculaires
WO2012085671A2 (fr) * 2010-12-21 2012-06-28 Omegatri As Antioxydants dans la poudre et les comprimés à base d'huiles de poissons
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
WO2015000986A1 (fr) * 2013-07-02 2015-01-08 International Nutrition Research Company Composition intervenant dans la regulation du dysfonctionnement des cycles de l'energie, de l'inflammation et de l'insulinoresistance et son utilisation notamment dans les maladies cardiometaboliques
FR3007985A1 (fr) * 2013-07-02 2015-01-09 Internat Nutrition Res Company Medicament pour la prevention et le traitement des facteurs de risques cardiometaboliques, en particulier maladies cardiovasculaires, pre-diabete, diabete de type ii et steatose hepatique
FR3007986A1 (fr) * 2013-07-02 2015-01-09 Internat Nutrition Res Company Medicament destine a lutter contre l'infertilite et la sous-fertilite en particulier dans le cadre d'une sous fertilite ou infertilite metabolique
FR3007987A1 (fr) * 2013-07-02 2015-01-09 Internat Nutrition Res Company Medicament pour la prevention et le traitement de l'atherosclerose et du survieillissement metabolique
WO2017180127A1 (fr) * 2016-04-14 2017-10-19 Lucey Michael Compositions combinatoires et leurs méthodes d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
CA2222278C (fr) * 1995-06-06 2008-05-13 Campbell Soup Company Complements alimentaires a base de mineraux pour repas dietetique
CA2251972A1 (fr) * 1996-04-17 1997-10-23 Merck & Co., Inc. Therapie combinatoire pour reduire les risques associes a une maladie cardiovasculaire
ES2179156T3 (es) * 1996-11-20 2003-01-16 Nutricia Nv Composicion nutricional que incluye grasas para el tratamiento del sindrome metabolico.

Also Published As

Publication number Publication date
AU3651102A (en) 2002-06-11
EP1339429A2 (fr) 2003-09-03
MXPA03004818A (es) 2003-09-10
WO2002043659A2 (fr) 2002-06-06
EP1339429A4 (fr) 2007-03-14
WO2002043659A3 (fr) 2002-09-06
JP2004514684A (ja) 2004-05-20

Similar Documents

Publication Publication Date Title
US20040018248A1 (en) Composition containing statins and calcium for improved cardiovascular health
CA2427618A1 (fr) Composition contenant des statines et du calcium destinee a ameliorer la sante cardiovasculaire
US20060105033A1 (en) Dietary composition containing conjugated linoleic acid and calcium for improved health
US8927012B2 (en) Multi-vitamin and mineral nutritional supplements
US5364644A (en) Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders
US6020383A (en) Method for reducing blood cholesterol and/or blood triglycerides
JP2002536306A (ja) レシチン圧縮調製物
JP4986321B2 (ja) 炎症性状態処置のための方法および組成物
US20160008300A1 (en) Compositions and Methods for Nutritional Supplementation
WO1999017612A1 (fr) Procede d'elaboration d'une preparation orale contenant de la serotonine, et methodes d'utilisation associees
KR20130046451A (ko) 심혈관 질환의 치료를 위한 폴리메톡시플라본 및 토코트리에놀의 생체이용율을 개선시키기 위한 조성물
US8557236B2 (en) Cardiovascular support supplement and compositions and methods thereof
EP0127297B1 (fr) Composition contenant des vitamines avec un taux d'absorption amélioré et méthode pour son administration
CA2427681A1 (fr) Composition dietetique contenant de l'acide linoleique conjugue et du calcium pour une meilleure sante
US5627152A (en) Method for increasing bodyweight
EP1541041B1 (fr) Compositions diététiques contre le stress
MXPA01007008A (es) Metodo para reducir colesterol en sangre y/o trigliceridos en sangre

Legal Events

Date Code Title Description
FZDE Dead